Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene ...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today ...
(“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has ...
Nearly 500 guests gathered at Cipriani 42nd Street for the Campaign to End MS Gala, emceed by Ginger Zee and honoring David Osmond and his family, as the Society kicked off its five-year, $1 billion ...
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today ...
Wandercraft today announced the acquisition of Ekso Bionics, Inc. from a subsidiary of ChronoScale Holdings Corporation (Nasdaq: CHRN), bringing together two leaders in robotic mobility. The two ...
Les patients traités par agonistes du GLP-1 rapportent plus souvent la modification de la couleur ou la perte d’un ongle ou ...
Nutraville is expanding its healthy-aging portfolio with Pineal Guardian Advanced, a liquid botanical formula that combines 11 nutritional and plant-based ingredients to support pineal gland wellness, ...
Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock. DALLA ...
Major shareholder announcement . Reference is made to the press release issued by Coloplast A/S on 4 September 2026 regarding the expected implementation of the generational chang ...
IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with ...
A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results